Sagimet Biosciences Series Stock Current Valuation
| SGMT Stock | 5.69 0.15 2.71% |
Valuation analysis of Sagimet Biosciences helps investors to measure Sagimet Biosciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Sagimet Biosciences' Enterprise Value Over EBITDA is comparatively stable compared to the past year. Enterprise Value Multiple is likely to gain to 0.63 in 2024, despite the fact that Enterprise Value is likely to grow to (17.5 M). Fundamental drivers impacting Sagimet Biosciences' valuation include:
Price Book 1.0733 | Enterprise Value 30.8 M | Enterprise Value Ebitda (1.93) | Price Sales 89.1811 | Enterprise Value Revenue 0.2759 |
Undervalued
Today
Please note that Sagimet Biosciences' price fluctuation is slightly risky at this time. Calculation of the real value of Sagimet Biosciences is based on 3 months time horizon. Increasing Sagimet Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Sagimet Biosciences' intrinsic value may or may not be the same as its current market price of 5.69, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.69 | Real 14.95 | Target 43.33 | Hype 5.91 | Naive 6.59 |
The intrinsic value of Sagimet Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sagimet Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sagimet Biosciences Series helps investors to forecast how Sagimet stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sagimet Biosciences more accurately as focusing exclusively on Sagimet Biosciences' fundamentals will not take into account other important factors: Sagimet Biosciences Series Company Current Valuation Analysis
Sagimet Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Sagimet Biosciences Current Valuation | 30.82 M |
Most of Sagimet Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sagimet Biosciences Series is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Sagimet Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Sagimet Biosciences is extremely important. It helps to project a fair market value of Sagimet Stock properly, considering its historical fundamentals such as Current Valuation. Since Sagimet Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sagimet Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sagimet Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Sagimet Biosciences Series has a Current Valuation of 30.82 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is notably lower than that of the firm.
Sagimet Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sagimet Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sagimet Biosciences could also be used in its relative valuation, which is a method of valuing Sagimet Biosciences by comparing valuation metrics of similar companies.Sagimet Biosciences is currently under evaluation in current valuation category among its peers.
Sagimet Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sagimet Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sagimet Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Sagimet Fundamentals
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (18.14) % | ||||
| Current Valuation | 30.82 M | ||||
| Shares Outstanding | 30.67 M | ||||
| Shares Owned By Insiders | 14.10 % | ||||
| Shares Owned By Institutions | 70.06 % | ||||
| Number Of Shares Shorted | 4.36 M | ||||
| Price To Book | 1.07 X | ||||
| Price To Sales | 89.18 X | ||||
| Revenue | 2 M | ||||
| EBITDA | (30.74 M) | ||||
| Net Income | (27.88 M) | ||||
| Total Debt | 65 K | ||||
| Book Value Per Share | 5.74 X | ||||
| Cash Flow From Operations | (23.77 M) | ||||
| Short Ratio | 1.37 X | ||||
| Earnings Per Share | (0.92) X | ||||
| Target Price | 32.6 | ||||
| Market Capitalization | 191.24 M | ||||
| Total Asset | 96.72 M | ||||
| Retained Earnings | (249.74 M) | ||||
| Working Capital | 90.99 M | ||||
| Net Asset | 96.72 M |
About Sagimet Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sagimet Biosciences Series's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sagimet Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sagimet Biosciences Series based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sagimet Stock Analysis
When running Sagimet Biosciences' price analysis, check to measure Sagimet Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sagimet Biosciences is operating at the current time. Most of Sagimet Biosciences' value examination focuses on studying past and present price action to predict the probability of Sagimet Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sagimet Biosciences' price. Additionally, you may evaluate how the addition of Sagimet Biosciences to your portfolios can decrease your overall portfolio volatility.